{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:06:41Z","timestamp":1790939201731,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma"],"published-print":{"date-parts":[[2002,6]]},"DOI":"10.3816\/clm.2002.n.011","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:09:59Z","timestamp":1221095399000},"page":"49-55","source":"Crossref","is-referenced-by-count":56,"title":["Proteasome Inhibitors in the Treatment of B-Cell Malignancies"],"prefix":"10.3816","volume":"3","author":[{"given":"David","family":"Schenkein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2002.n.011_bib1","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2002.n.011_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/jsre.2001.6194","article-title":"Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome","volume":"100","author":"Bold","year":"2001","journal-title":"J Surg Res"},{"key":"10.3816\/CLM.2002.n.011_bib3","first-page":"3535","article-title":"Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition","volume":"61","author":"Cusack","year":"2001","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2002.n.011_bib4","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2002.n.011_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jcb.1150","article-title":"26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer","volume":"82","author":"Shah","year":"2001","journal-title":"J Cell Biochem"},{"key":"10.3816\/CLM.2002.n.011_bib6","first-page":"186a","article-title":"Dose-dependent inhibition of 20S proteasome results in serum IL-6 and PSA decline in patients (pts) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341","volume":"20","author":"Logothetis","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2002.n.011_bib7","first-page":"85a","article-title":"A phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies","volume":"20","author":"Aghajanian","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2002.n.011_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/386463a0","article-title":"Structure of 20S proteasome from yeast at 2.4 \u00c5 resolution","volume":"386","author":"Groll","year":"1997","journal-title":"Nature"},{"key":"10.3816\/CLM.2002.n.011_bib9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1126\/science.7725097","article-title":"Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 \u00c5 resolution","volume":"268","author":"Lowe","year":"1995","journal-title":"Science"},{"key":"10.3816\/CLM.2002.n.011_bib10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1101\/SQB.1995.060.01.056","article-title":"Catalytic mechanism of the 20S proteasome of thermoplasma acidophilum revealed by x-ray crystallography","volume":"60","author":"Stock","year":"1995","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"10.3816\/CLM.2002.n.011_bib11","doi-asserted-by":"crossref","first-page":"14831","DOI":"10.1074\/jbc.275.20.14831","article-title":"Why does threonine, and not serine, function as the active site nucleophile in proteasomes?","volume":"275","author":"Kisselev","year":"2000","journal-title":"J Biol Chem"},{"key":"10.3816\/CLM.2002.n.011_bib12","doi-asserted-by":"crossref","first-page":"12504","DOI":"10.1073\/pnas.95.21.12504","article-title":"Cleavage motifs of the yeast 20S proteasome \u03b2 subunits deduced from digests of enolase 1","volume":"95","author":"Nussbaum","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2002.n.011_bib13","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/sj.leu.2401812","article-title":"Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1\/CIP1, and induction of apoptosis are independent markers of proteasome inhibition","volume":"14","author":"An","year":"2000","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2002.n.011_bib14","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1182\/blood.V91.12.4624","article-title":"Inhibition of nuclear factor \u03baB activation attenuates apoptosis resistance in lymphoid cells","volume":"91","author":"Jeremias","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.011_bib15","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/(SICI)1097-4644(20000315)76:4<596::AID-JCB8>3.0.CO;2-N","article-title":"The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67","volume":"76","author":"Wu","year":"2000","journal-title":"J Cell Biochem"},{"key":"10.3816\/CLM.2002.n.011_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1126\/science.7624798","article-title":"Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27","volume":"269","author":"Pagano","year":"1995","journal-title":"Science"},{"key":"10.3816\/CLM.2002.n.011_bib17","doi-asserted-by":"crossref","first-page":"10815","DOI":"10.1073\/pnas.93.20.10815","article-title":"p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts","volume":"93","author":"Dietrich","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2002.n.011_bib18","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1006\/bbrc.1999.1291","article-title":"Phosphorylation and proteasomedependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage","volume":"262","author":"Chadebech","year":"1999","journal-title":"Biochm Biophys Res Commun"},{"key":"10.3816\/CLM.2002.n.011_bib19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1073\/pnas.92.2.552","article-title":"Activation of NF-\u03baB requires proteolysis of the inhibitor I\u03baB-\u03b1: signal-induced phosphorylation of I\u03baB-a alone does not release active NF-kB","volume":"92","author":"Lin","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2002.n.011_bib20","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1074\/jbc.271.13.7844","article-title":"Role of IkBa ubiquitination in signal-induced activation of NF-\u03baB in vivo","volume":"271","author":"Roff","year":"1996","journal-title":"J Biol Chem"},{"key":"10.3816\/CLM.2002.n.011_bib21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/0092-8674(94)90379-4","article-title":"p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest","volume":"76","author":"Dulic","year":"1994","journal-title":"Cell"},{"key":"10.3816\/CLM.2002.n.011_bib22","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1126\/science.274.5293.1652","article-title":"How proteolysis drives the cell cycle","volume":"274","author":"King","year":"1996","journal-title":"Science"},{"key":"10.3816\/CLM.2002.n.011_bib23","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1365-2141.1999.01388.x","article-title":"Increased sensitivity of CLLderived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin","volume":"105","author":"Masdehors","year":"1999","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2002.n.011_bib24","first-page":"473a","article-title":"Proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents and overcomes chemoresistance through inhibition of the NF-\u03baB pathway","volume":"98","author":"Ma","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.011_bib25","first-page":"4342","article-title":"Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor","volume":"58","author":"Orlowski","year":"1998","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2002.n.011_bib26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1073\/pnas.94.3.855","article-title":"Activation of the cell death program by inhibition of proteasome function","volume":"94","author":"Drexler","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2002.n.011_bib27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.V95.2.619","article-title":"Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma","volume":"95","author":"Chiarle","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.011_bib28","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/sj.cdd.4400436","article-title":"Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclindependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts","volume":"5","author":"An","year":"1998","journal-title":"Cell Death Differ"},{"key":"10.3816\/CLM.2002.n.011_bib29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI11991","article-title":"Control of oncogenesis and cancer therapy resistance by the transcription factor NF-\u03baB","volume":"107","author":"Baldwin","year":"2001","journal-title":"J Clin Invest"},{"key":"10.3816\/CLM.2002.n.011_bib30","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.1073\/pnas.92.24.11259","article-title":"Signal-induced degradation of I\u03baB\u03b1 requires site-specific ubiquitination","volume":"92","author":"Scherer","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2002.n.011_bib31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1101\/gad.13.3.284","article-title":"Signal-induced ubiquitination of I\u03baB\u03b1 by the F-box protein Slimb\/\u03b2-TrCP","volume":"13","author":"Spencer","year":"1999","journal-title":"Genes Dev"},{"key":"10.3816\/CLM.2002.n.011_bib32","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1101\/gad.13.3.270","article-title":"The SCF\u03b2-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in I\u03baB\u03b1 and b-catenin and stimulates I\u03baB\u03b1 ubiquitination in vitro","volume":"13","author":"Winston","year":"1999","journal-title":"Genes Dev"},{"key":"10.3816\/CLM.2002.n.011_bib33","doi-asserted-by":"crossref","first-page":"10599","DOI":"10.1073\/pnas.92.23.10599","article-title":"Stimulation-dependent IkBa phosphorylation marks the NF-kB inhibitor for degradation via the ubiquitinproteasome pathway","volume":"92","author":"Alkalay","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2002.n.011_bib34","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1074\/jbc.271.1.376","article-title":"Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I\u03baB\u03b1","volume":"271","author":"Baldi","year":"1996","journal-title":"J Biol Chem"},{"key":"10.3816\/CLM.2002.n.011_bib35","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1101\/gad.9.13.1586","article-title":"Signal-induced site-specific phosphorylation targets IkBa to the ubiquitin-proteasome pathway","volume":"9","author":"Chen","year":"1995","journal-title":"Genes Dev"},{"key":"10.3816\/CLM.2002.n.011_bib36","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1128\/MCB.20.8.2687-2695.2000","article-title":"The Rel\/NF-\u03baB family directly activates expression of the apoptosis inhibitor Bcl-x(L)","volume":"20","author":"Chen","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.3816\/CLM.2002.n.011_bib37","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1126\/science.281.5383.1680","article-title":"NF-kB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation","volume":"281","author":"Wang","year":"1998","journal-title":"Science"},{"key":"10.3816\/CLM.2002.n.011_bib38","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1128\/MCB.19.9.5923","article-title":"NF-\u03baB induces expression of the Bcl-2 homologue A1\/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis","volume":"19","author":"Wang","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.3816\/CLM.2002.n.011_bib39","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1101\/gad.13.4.382","article-title":"The prosurvival Bcl-2 homolog Bfl-1\/A1 is a direct transcriptional target of NF-\u03baB that blocks TNFa-induced apoptosis","volume":"13","author":"Zong","year":"1999","journal-title":"Genes Dev"},{"key":"10.3816\/CLM.2002.n.011_bib40","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1073\/pnas.90.6.2532","article-title":"Mutual regulation of the transcriptional activator NF-\u03baB and its inhibitor, I\u03baB\u03b1","volume":"90","author":"Brown","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2002.n.011_bib41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.leu.2401705","article-title":"Transcription factor NF-\u03baB is constitutively activated in acute lymphoblastic leukemia cells","volume":"14","author":"Kordes","year":"2000","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2002.n.011_bib42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(00)00019-2","article-title":"New insights into role of microenvironment in multiple myeloma","volume":"355","author":"Tricot","year":"2000","journal-title":"Lancet"},{"key":"10.3816\/CLM.2002.n.011_bib43","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1365-2141.2001.03102.x","article-title":"Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis","volume":"115","author":"Ni","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2002.n.011_bib44","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1038\/sj.onc.1203768","article-title":"Paclitaxel sensitivity of breast cancer cells with constitutively active NF-\u03baB is enhanced by I\u03baB\u03b1 super-repressor and parthenolide","volume":"19","author":"Patel","year":"2000","journal-title":"Oncogene"},{"key":"10.3816\/CLM.2002.n.011_bib45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc780","article-title":"NF-\u03baB in cancer: from innocent bystander to major culprit","volume":"2","author":"Karin","year":"2002","journal-title":"Nature Reviews"},{"key":"10.3816\/CLM.2002.n.011_bib46","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0093-7754(01)90036-3","article-title":"The role of nuclear factor-\u03baB in the biology and treatment of multiple myeloma","volume":"28","author":"Berenson","year":"2001","journal-title":"Sem Oncol"},{"key":"10.3816\/CLM.2002.n.011_bib47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1054\/drup.1999.0094","article-title":"NF-\u03baB and chemoresistance: potentiation of cancer drugs via inhibition of NF-\u03baB","volume":"2","author":"Cusack","year":"1999","journal-title":"Drug Resist Updat"},{"key":"10.3816\/CLM.2002.n.011_bib48","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/bjc.1998.183","article-title":"The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo-and radioresistant human chronic lymphocytic leukemia lymphocytes to TNF-\u03b1\u2013initiated apoptosis","volume":"77","author":"Delic","year":"1998","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2002.n.011_bib49","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ijc.1040","article-title":"Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells","volume":"96","author":"Kurland","year":"2001","journal-title":"Int J Cancer"},{"key":"10.3816\/CLM.2002.n.011_bib50","series-title":"Cancer: Principles and Practice of Oncology","first-page":"3","article-title":"Essentials of molecular biology: basic principles","author":"Liotta","year":"2001"},{"key":"10.3816\/CLM.2002.n.011_bib51","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/modpathol.3880306","article-title":"Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells","volume":"14","author":"Izban","year":"2001","journal-title":"Mod Pathol"},{"key":"10.3816\/CLM.2002.n.011_bib52","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0360-3016(00)00516-2","article-title":"Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition","volume":"47","author":"Pajonk","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.3816\/CLM.2002.n.011_bib53","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","article-title":"Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids","volume":"8","author":"Adams","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"10.3816\/CLM.2002.n.011_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/canjclin.50.1.7","article-title":"Cancer Statistics, 2000","volume":"50","author":"Greenlee","year":"2000","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CLM.2002.n.011_bib55","first-page":"377a","article-title":"Myeloma cell adhesion to fibronectin activates NF-\u03baB and induces the expression of genes contributing to cell adhesionmediated drug resistance","volume":"98","author":"Landowski","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.011_bib56","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0093-7754(01)90036-3","article-title":"The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma","volume":"28","author":"Berenson","year":"2001","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2002.n.011_bib57","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/1074-7613(95)90030-6","article-title":"The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression","volume":"93","author":"Read","year":"1995","journal-title":"Immunity"},{"key":"10.3816\/CLM.2002.n.011_bib58","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0091-6749(99)70369-6","article-title":"Proteasome inhibition: a novel mechanism to combat asthma","volume":"104","author":"Elliott","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.3816\/CLM.2002.n.011_bib59","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood.V93.9.3064","article-title":"Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma","volume":"93","author":"Vacca","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.011_bib60","first-page":"3812s","article-title":"Proteasome inhibitor PS-341 is effective as an anti-angiogenic agent in the treatment of human pancreatic carcinoma via the inhibition of NF-kB and subsequent inhibition of vascular endothelial growth factor production","volume":"5","author":"Harbison","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2002.n.011_bib61","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1006\/bbrc.1998.8604","article-title":"The proteasome is involved in angiogenesis","volume":"246","author":"Oikawa","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.3816\/CLM.2002.n.011_bib62","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm0102-68","article-title":"Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning","volume":"8","author":"Shipp","year":"2002","journal-title":"Nature Med"},{"key":"10.3816\/CLM.2002.n.011_bib63","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor-kB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J Exp Med"},{"key":"10.3816\/CLM.2002.n.011_bib64","first-page":"456a","article-title":"Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells","volume":"98","author":"Pham","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.011_bib65","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","article-title":"Proteasome inhibition measurements: clinical application","volume":"46","author":"Lightcap","year":"2000","journal-title":"Clin Chem"},{"key":"10.3816\/CLM.2002.n.011_bib66","first-page":"86a","article-title":"Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancer","volume":"20","author":"Nix","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2002.n.011_bib67","first-page":"11a","article-title":"Phase II study of the proteasome inhibitor PS-341 in multiple myeloma (MM) patients (pts) with relapsed\/refractory disease","volume":"21","author":"Richardson","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2002.n.011_bib68","first-page":"774a","article-title":"Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy","volume":"98","author":"Richardson","year":"2001","journal-title":"Blood"}],"container-title":["Clinical Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152696551170241X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152696551170241X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:09:03Z","timestamp":1588918143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152696551170241X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["S152696551170241X"],"URL":"https:\/\/doi.org\/10.3816\/clm.2002.n.011","relation":{},"ISSN":["1526-9655"],"issn-type":[{"value":"1526-9655","type":"print"}],"subject":[],"published":{"date-parts":[[2002,6]]}}}